Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0007 Transporter Info
Gene Name SLC47A1
Transporter Name Multidrug and toxin extrusion protein 1
Gene ID
55244
UniProt ID
Q96FL8
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Ranitidine

            4 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ranitidine inhibits the transportation of Metformin by SLC47A1 (IC50 = 18.9 microM) [1]

Affected Drug/Substrate

 Metformin Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-MATE1

  DT Modulation 2

 Ranitidine inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 17.5 microM) [1]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-MATE1

  DT Modulation 3

 Ranitidine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 25.4 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  DT Modulation 4

 Ranitidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Quinine

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quinine inhibits the transportation of 1-methyl-4-phenylpyridinium by SLC47A1 (IC50 = 1.9 microM) [4]

Affected Drug/Substrate

 1-methyl-4-phenylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-MATE1

  DT Modulation 2

 Quinine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 29.2 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  DT Modulation 3

 Quinine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Ritonavir

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ritonavir inhibits the transportation of Metformin by SLC47A1 (IC50 = 15.4 microM) [1]

Affected Drug/Substrate

 Metformin Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-MATE1

  DT Modulation 2

 Ritonavir inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 13.9 microM) [1]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-MATE1

  DT Modulation 3

 Ritonavir inhibits the activity of SLC47A1 (IC50 = 3.1 microM) [5]

  Mitoxantrone

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mitoxantrone inhibits the transportation of Metformin by SLC47A1 (IC50 = 4.4 microM) [1]

Affected Drug/Substrate

 Metformin Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-MATE1

  DT Modulation 2

 Mitoxantrone inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 5.2 microM) [1]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-MATE1

  Sirolimus

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rapamycin inhibits the transportation of Metformin by SLC47A1 (IC50 = 3.27 microM) [1]

Affected Drug/Substrate

 Metformin Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-MATE1

  DT Modulation 2

 Rapamycin inhibits the transportation of Tetraethylammonium by SLC47A1 (IC50 = 3.51 microM) [1]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-MATE1

  Chloroquine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chloroquine inhibits the transportation of Metformin by SLC47A1 (IC50 = 2.5 microM) [6]

Affected Drug/Substrate

 Metformin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  DT Modulation 2

 Chloroquine inhibits the activity of SLC47A1 [6]

  Cimetidine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cimetidine inhibits the transportation of Metformin by SLC47A1 (Ki = 3.8 microM) [7]

Affected Drug/Substrate

 Metformin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  DT Modulation 2

 Cimetidine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 1.1 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Amantadine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amantadine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 111.8 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  DT Modulation 2

 Amantadine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Cetirizine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cetirizine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 371.2 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  DT Modulation 2

 Cetirizine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Metformin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Metformin inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 666.9 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  DT Modulation 2

 Metformin modulates the activity of SLC47A1 [11]

  Carvedilol

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carvedilol inhibits the activity of SLC47A1 (IC50 = 103 microM) [10]

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  DT Modulation 2

 Carvedilol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Chlorpheniramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlorpheniramine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 87.6 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Desipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Desipramine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 55.7 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Diltiazem

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diltiazem inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 12.5 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Diphenhydramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diphenhydramine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 87 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Disopyramide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Disopyramide inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 83.8 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Famotidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Famotidine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 0.6 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Imipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Imipramine inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 42 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Pramipexole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pramipexole inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 141.4 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Procainamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Procainamide inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 217 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Verapamil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Verapamil inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 27.5 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Cobicistat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cobicistat inhibits the activity of SLC47A1 (IC50 = 4.4 microM) [5]

  Telaprevir

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Telaprevir inhibits the activity of SLC47A1 (IC50 = 0.023 microM) [15]

  Azacitidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Azacitidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Buspirone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Buspirone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Chlorhexidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Chlorhexidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Ciclopirox

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ciclopirox inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Clonidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clonidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Cortisone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cortisone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Dexamethasone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dexamethasone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Diclofenac

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diclofenac inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Dihydroergotamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dihydroergotamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Domperidone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Domperidone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Enalapril

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Enalapril inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Epinastine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Epinastine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Erythromycin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Erythromycin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Ethinyl Estradiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ethinyl estradiol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Furosemide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Furosemide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Gabexate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Gabexate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Granisetron

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Granisetron inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Indomethacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Indomethacin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Irbesartan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Irbesartan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Irinotecan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Irinotecan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Levofloxacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Levofloxacin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Lidocaine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lidocaine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Losartan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Losartan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Methylergonovine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methylergonovine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Prazosin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Prazosin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Rimantadine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rimantadine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Spironolactone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Spironolactone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Sulfacetamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sulfacetamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Sumatriptan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sumatriptan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Telmisartan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Telmisartan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Thiabendazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Thiabendazole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Topotecan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Topotecan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Tubocurarine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tubocurarine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Zafirlukast

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zafirlukast inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Crizotinib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Crizotinib inhibits the transportation of Creatinine by SLC47A1 [16]

Affected Drug/Substrate

 Creatinine Modulation Type Inhibition

Cell System

 MATE1-overexpressing cells

  Amiloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amiloride inhibits the activity of SLC47A1 [18]

  Quinidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quinidine inhibits the activity of SLC47A1 [18]

  Methotrexate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methotrexate increases the expression of SLC47A1 [19]

  Copper Sulfate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Copper Sulfate inhibits the expression of SLC47A1 [20]

  Medroxyprogesterone Acetate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Medroxyprogesterone Acetate inhibits the expression of SLC47A1 [21]

  Cytarabine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cytarabine inhibits the expression of SLC47A1 [22]

  Zoledronic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zoledronic Acid inhibits the expression of SLC47A1 [23]

  Rifampin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rifampin increases the expression of SLC47A1 [24]

  Cisplatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cisplatin increases the expression of SLC47A1 [25]

  Mebendazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mebendazole inhibits the expression of SLC47A1 [26]

  Urethane

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Urethane inhibits the expression of SLC47A1 [27]

  Acetaminophen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acetaminophen inhibits the expression of SLC47A1 [28]

  Sunitinib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sunitinib inhibits the expression of SLC47A1 [29]

  Pyrimethamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pyrimethamine inhibits the activity of SLC47A1 [30]

  Cyclosporine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclosporine inhibits the expression of SLC47A1 [31]

  Estradiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Estradiol increases the expression of SLC47A1 [32]

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic Acid increases the expression of SLC47A1 [33]

  Trimethoprim

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Trimethoprim inhibits the activity of SLC47A1 [6]

  Plazomicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Plazomicin inhibits the activity of SLC47A1 [34]

  Itraconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Itraconazole inhibits the activity of SLC47A1 [35]

  Ketoconazole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ketoconazole inhibits the activity of SLC47A1 [35]

Drug in Phase 4 Trial

  Talipexole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Talipexole inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 66 microM) [2]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

Drug in Phase 3 Trial

  Vitamin E

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vitamin E increases the expression of SLC47A1 [36]

  Triclosan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Triclosan inhibits the expression of SLC47A1 [41]

  Sulforafan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sulforafan increases the expression of SLC47A1 [43]

Drug in Phase 2 Trial

  Camostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Camostat inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  MS-275

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 MS-275 increases the expression of SLC47A1 [38]

  Bisphenol A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bisphenol A inhibits the activity of SLC47A1 [39]

Drug in Phase 1/2 Trial

  CB3304

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 CB3304 inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

Drug in Phase 1 Trial

  Sodium arsenite

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sodium arsenite inhibits the expression of SLC47A1 [40]

Discontinued Drug

  DX-619

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 DX-619 inhibits the transportation of Creatinine by SLC47A1 (Ki = 0.82 microM) [12]

Affected Drug/Substrate

 Creatinine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

Patented Pharmaceutical Agent

  ICG-001

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 ICG-001 increases the expression of SLC47A1 [37]

Drug Withdrawn

  Astemizole

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Astemizole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Bithionol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Bithionol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Phenacetin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenacetin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC47A1 [3]

Affected Drug/Substrate

 4-(4-(dimethylamino)styryl)-N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

Natural Product

  Cigarette smoke condensate

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cigarette smoke condensate inhibits the transportation of Verapamil by repressing mRNA expression of SLC47A1 (IC50 = 6.1 microM) [8]

Affected Drug/Substrate

 Verapamil Modulation Type Inhibition

Cell System

 Human hepatoma HepaRG cells-MATE1

  DT Modulation 2

 Cigarette smoke condensate inhibits the activity of SLC47A1 (IC50 = 6.1 microM) [9]

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Allethrin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Allethrin inhibits the transportation of Verapamil by SLC47A1 (IC50 = 50.2 microM) [13]

Affected Drug/Substrate

 Verapamil Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Tetramethrin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tetramethrin inhibits the transportation of Verapamil by SLC47A1 (IC50 = 47.5 microM) [13]

Affected Drug/Substrate

 Verapamil Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  3-methylquercetin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Isorhamnetin inhibits the transportation of Tetraethylammonium by SLC47A1 (Ki = 0.32 microM) [14]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

  Green tea

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Green tea inhibits the transportation of Metformin by SLC47A1 [17]

Affected Drug/Substrate

 Metformin Modulation Type Inhibition

Cell System

 Human enterocyte-like 2 cell (Caco-2)-MATE1

  Epigallocatechin gallate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Epigallocatechin gallate inhibits the transportation of Metformin by SLC47A1 [17]

Affected Drug/Substrate

 Metformin Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-MATE1

  Methyleugenol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methyleugenol inhibits the expression of SLC47A1 [44]

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tobacco Smoke Pollution inhibits the expression of SLC47A1 [47]

  Rhein

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rhein up-regulated the expressions of SLC47A1 [48]

Cell System

 NRK-52E cells

Environmental toxicant

  Polychlorinated dibenzodioxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Polychlorinated dibenzodioxin inhibits the expression of SLC47A1 [8]

  Tetrabromobisphenol A

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tetrabromobisphenol A inhibits the activity of SLC47A1 [39]

Mycotoxins

  Aflatoxin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aflatoxin B1 inhibits the expression of SLC47A1 [46]

Acute Toxic Substance

  Paraquat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Paraquat increases the expression of SLC47A1 [45]

Carcinogen

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzo(a)pyrene inhibits the expression of SLC47A1 [44]

Health and Environmental Toxicant

  1-methyl-4-phenylpyridinium

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 1-methyl-4-phenylpyridinium inhibits the activity of SLC47A1 [18]

  Diethylhexyl Phthalate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diethylhexyl Phthalate inhibits the expression of SLC47A1 [42]
References
1 Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
2 Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 2009 Apr;329(1):185-91.
3 Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 2013 Feb 14;56(3):781-795.
4 Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther. 2012 Jun;341(3):743-55.
5 No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted With Ritonavir or Cobicistat. J Pharm Sci. 2019 Apr 26. pii: S0022-3549(19)30289-8.
6 Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
7 Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 2012 Feb;340(2):393-403.
8 Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016 Jul 1;363-364:58-71.
9 Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
10 Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharm Res. 2018 Sep 6;35(11):204.
11 Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701.
12 Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther. 2011 Jan;89(1):81-8.
13 Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin. PLoS One. 2017 Jan 18;12(1):e0169480.
14 Components of foods inhibit a drug exporter, human multidrug and toxin extrusion transporter 1. Biol Pharm Bull. 2014;37(2):292-7.
15 Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
16 Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1. Sci Rep. 2018 Jun 18;8(1):9237.
17 Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS One. 2015 Oct 1;10(10):e0139370.
18 Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney. Drug Metab Dispos. 2006 Nov;34(11):1868-74.
19 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
20 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
21 Effects of medroxyprogesterone acetate on gene expression in myometrial explants from pregnant women. J Clin Endocrinol Metab. 2010 Dec;95(12):E437-47.
22 Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
23 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
24 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
25 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
26 Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis. Toxicol In Vitro. 2017 Sep;43:87-91.
27 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
28 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
29 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761.
30 Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid. Chem Biol Interact. 2020 Jun 1;324:109097.
31 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
32 17 beta-Estradiol Activates HSF1 via MAPK Signaling in ER alpha-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533.
33 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
34 No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Jan 3.
35 Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. Drug Metab Dispos. 2016 Mar;44(3):453-9.
36 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
37 Altering cancer transcriptomes using epigenomic inhibitors. Epigenetics Chromatin. 2015 Feb 24;8:9.
38 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
39 Inhibition of SLC drug transporter activities by environmental bisphenols. Toxicol In Vitro. 2017 Apr;40:34-44.
40 Cellular and Molecular Effects of Prolonged Low-Level Sodium Arsenite Exposure on Human Hepatic HepaRG Cells. Toxicol Sci. 2018 Apr 1;162(2):676-687.
41 Transcriptome and DNA Methylome Dynamics during Triclosan-Induced Cardiomyocyte Differentiation Toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
42 Di-(2-ethylhexyl)-phthalate induces apoptosis via the PPAR Gamma/PTEN/AKT pathway in differentiated human embryonic stem cells. Food Chem Toxicol. 2019 Sep;131:110552.
43 Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. Food Chem Toxicol. 2020 Feb;136:111047.
44 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
45 CD34+ derived macrophage and dendritic cells display differential responses to paraquat. Toxicol In Vitro. 2021 Sep;75:105198.
46 Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 2016 Mar 28;350-352:31-9.
47 Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
48 Protective effect of Rhein against vancomycin-induced nephrotoxicity through regulating renal transporters and Nrf2 pathway. Phytother Res. 2022 Nov;36(11):4244-4262.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.